Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Belluscura's Enterprise Value is £2.48 Mil.
Belluscura's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2024 was £-7.65 Mil. Therefore, Belluscura's EV-to-OCF for today is -0.32.
The historical rank and industry rank for Belluscura's EV-to-OCF or its related term are showing as below:
LSE:BELL's EV-to-OCF is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 7.78 * Ranked among companies with meaningful EV-to-OCF only.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Belluscura's share price for today is £0.0075.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Belluscura's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was £-0.103.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Belluscura EV-to-OCF Related Terms
Belluscura EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Belluscura's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Belluscura's current Enterprise Value is £2.48 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Belluscura's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2024 was £-7.65 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Belluscura (LSE:BELL) has a EV-to-OCF of -0.32 as of Aug. 19, 2026.
Is Belluscura's EV-to-OCF too high?
Belluscura's current EV-to-OCF is -0.32.
How does Belluscura's EV-to-OCF compare to ABT and BSX?
Belluscura's EV-to-OCF of -0.32 can be compared against companies in the Medical Devices & Instruments industry. The industry median EV-to-OCF is 7.78. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.78, based on 851 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Belluscura's current EV-to-OCF is -0.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Belluscura stock overvalued right now?
Belluscura (LSE:BELL) has a current EV-to-OCF of -0.32. The current EV-to-OCF is -0.32. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Belluscura (LSE:BELL), the current EV-to-OCF is -0.32 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Belluscura PLC is a medical device company. Its first product, the X-PLOR, is a lightweight FDA-cleared portable oxygen concentrator designed to replace larger, metal oxygen tanks and heavier portable oxygen concentrator devices. The company has only one operating segment being the sale of oxygen concentrators in the United States. The X-PLO2R weighs less than 1.5kg (3.25 lbs) and it is the first modular portable oxygen concentrator it will generate more oxygen by weight than any other FDA-cleared POC in its class. It either owns or exclusively licenses a total of 26 patents and applications relating to oxygen enrichment devices and treatments.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:BELL has been successfully added to your 
